🇺🇸 Methyprednisolone sodium succinate in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 13

Most-reported reactions

1. Condition Aggravated — 3 reports (23.08%)
2. Pyrexia — 2 reports (15.38%)
3. Agranulocytosis — 1 report (7.69%)
4. Anaemia Postoperative — 1 report (7.69%)
5. Aphasia — 1 report (7.69%)
6. Aphthous Stomatitis — 1 report (7.69%)
7. Apnoea Neonatal — 1 report (7.69%)
8. Bradycardia — 1 report (7.69%)
9. Brain Oedema — 1 report (7.69%)
10. Cardiac Arrest — 1 report (7.69%)

Source database →

Frequently asked questions

Is Methyprednisolone sodium succinate approved in United States?

Methyprednisolone sodium succinate does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Methyprednisolone sodium succinate in United States?

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.